<DOC>
	<DOCNO>NCT00100282</DOCNO>
	<brief_summary>This multi-center , double-blind , inpatient study follow outpatient , placebo-controlled , single-dose , dose-escalation evaluation safety tolerability PPI-1019 patient mild-moderate Alzheimer ’ disease ( AD ) . Up 12 sequential cohort 8 patient ( 6 active 2 placebo ) give single PPI-1019 dose intravenously ( IV ) 1 minute order determine maximum tolerate dose ( MTD ) . The MTD dose immediately not-tolerated dose .</brief_summary>
	<brief_title>Safety Study PPI-1019 Patients With Mild-Moderate Alzheimer ’ Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Patient ability understand requirement study , provide write informed consent , abide requirement study . Patient caregiver willing assist patient ’ involvement study . Patient male female age 50 80 body mass index ( BMI ) 31 . Females must postmenopausal least 1 year surgically sterilize . Patient must cognitive deficit present least one year meet DSM IV criterion Alzheimer ’ Disease meet National Institute Neurological Communicative Disorders Stroke/Alzheimer ’ Disease Related Disorders Association ( NINCDS/ADRDA ) criterion presence probable Alzheimer ’ Disease . Patient ’ severity Alzheimer ’ disease must mildmoderate , document Mini Mental State Exam ( MMSE ) score 1226 . Patient computerize tomography ( CT ) scan magnetic resonance imaging ( MRI ) within prior 12 month compatible diagnosis probable AD . If patient treat Alzheimer ’ disease , must single agent ( donepezil , rivastigmine , galantamine , memantine ) dose stable least 3 month . Patient otherwise good general health . Treatment hypertension 2 medication hyperlipidemia one agent acceptable provide drug dosage stable least 30 day . Patient agree abstain alcohol take drug , dietary supplement , herbal therapy Mylanta® , ibuprofen , multivitamin length study ( screen followup visit Day 22 ) . Patient agrees donate blood blood product participate study least 60 day discontinue study . Patient participate clinical trial another investigational drug device , take experimental drug within 30 day prior screen . Patient history compatible vascular dementia evidence score 5 great modify Hachinski Ischemia Scale . Patient evidence clinically significant cardiovascular , renal , hepatic , gastrointestinal , neurological , metabolic disease within past 6 month ( determined medical history , ECG result , chest xray , physical examination ) . Findings potential significance must discuss appropriate sponsor clinician ( PRAECIS ’ designee ) prior patient entry . Patient systolic blood pressure ( sit ) great 150 mmHg , diastolic ( sit ) great 95 mmHg , decrease systolic blood pressure 30 mmHg upon stand 2 minute sit supine position , pulse ( sit supine ) less 55 great 85 . Patient visual , hearing , communication disability impair ability participate study . Patient intend use concomitant medication study describe Inclusion Criteria . Patient take concomitant medication without approval investigator within 7 day prior Day 1 . Patient test positive drug abuse ( benzodiazepine , narcotic , amphetamine , barbiturate , sedative , hypnotic , cocaine , phencyclidine , alcohol , cannabinoids ) drug screen Day 1 . Patient elevation ( &gt; 1.2 x ULN ) screen Day 1 ALT , AST , bilirubin , creatinine , blood urea nitrogen , alkaline phosphatase . Patient screen Day 1 laboratory value outside normal range deem clinically significant investigator .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Mild-moderate Alzheimer 's disease</keyword>
</DOC>